Linked Life Data

1912035

Source:http://linkedlifedata.com/resource/pubmed/id/1912035

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1991-11-12
pubmed:abstractText
The effects of mafosfamid on lymphokine-activated killer (LAK) cells were examined, using a newly developed clonogenic microassay with tumor target cells instead of the common 51Cr release. When nonadherent peripheral blood mononuclear effector cells were exposed to 1 x 10(-9) or 1 x 10(-8) M mafosfamid 1 h prior to activation with interleukin 2 (IL-2), LAK-cell activity increased, resulting in fewer colonies of human KB squamous carcinoma cells than without mafosfamid treatment. In contrast, when effector cells were exposed to mafosfamid after IL-2 activation LAK-cell activity was inhibited. Notably, the in vitro immunomodulatory effects of mafosfamid were detected at concentrations 100-1000 times below those shown to be cytotoxic. Although the mechanisms remain to be elucidated, our results might be an in vitro representation of the known in vivo immunostimulation of low doses of cyclophosphamide.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0939-5555
pubmed:author
pubmed:issnType
Print
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
79-83
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Effects of low-dose mafosfamid on the lymphokine-activated killer cell activity of peripheral blood mononuclear cells determined by a clonogenic microassay.
pubmed:affiliation
Institut für Pharmazie der Freien Universität Berlin, FRG.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't